|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Pathology and Molecular
Medicine, McMaster University and the Hamilton Civic Hospitals Research
Center, Hamilton, ON, Canada.
We have previously demonstrated that long-term heparin treatment
causes cancellous bone loss in rats due in part to an increase in the
number of osteoclasts lining the trabecular bone surface. In the
present study, we investigated this phenomenon by examining the
ability of heparin to synergistically enhance interleukin-11 (IL-11)-induced osteoclast formation. Treatment of murine calvaria and
bone marrow cells with IL-11 was found to induce the formation of
tartrate-resistant acid phosphatase-positive (TRAP+)
multinucleated cells (MNCs) in a dose-dependent fashion. No effect was
seen when cocultures were treated with heparin alone. However, when
cocultures were treated with both IL-11 and heparin, IL-11's ability
to induce TRAP+ MNC formation was enhanced 6-fold. In
an attempt to resolve the mechanism responsible for this effect, we
examined the ability of heparin to influence IL-11 signaling using
murine calvaria cells. Heparin was found to enhance both IL-11-induced
STAT3-DNA complex formation and transactivation without altering either STAT3 (signal transducer and activator of transcription-3) tyrosine or
serine phosphorylation. Heparin was also found to enhance IL-11's ability to induce the expression of both receptor activator of nuclear
factor- Osteoporosis is a well-recognized complication of
long-term heparin use, with up to one third of all patients receiving
long-term heparin experiencing subclinical reductions in bone
density.1-12 Heparin is currently given long-term to
prevent and treat venous thromboembolism during pregnancy, to prevent
systemic embolism in pregnant women with mechanical heart valves, and
to prevent pregnancy loss in women with antiphospholipid antibodies.
Long-term heparin therapy is also indicated in nonpregnant patients
with venous thromboembolism who have developed recurrences despite "adequate" oral anticoagulant therapy and in some patients who are
immobilized for prolonged periods and who require ongoing thromboprophylaxis.11
In an attempt to resolve some of the issues surrounding long-term
heparin therapy, we developed an animal model of heparin-induced osteoporosis. Using this model, we demonstrated that heparin induces both a time- and dose-dependent decrease in cancellous bone volume and
that this results from a decrease in bone formation and an increase in
bone resorption.13,14 We have also shown through histomorphometric analysis that these effects result from decreased osteoblast numbers as well as an increase in osteoclast number and
activity. However, using this model we were unable to determine the
exact mechanism by which heparin causes such profound effects on either
the osteoblast or the osteoclast.
Interleukin-11 (IL-11) is a member of the gp130 receptor family of
cytokines, a group that includes IL-6, leukemia inhibitory factor
(LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF),
and cardiotrophin-1 (CT-1). We as well as others have demonstrated
that these cytokines are produced by osteoblasts15-17 and that members of this cytokine family, including IL-11, are all
capable of stimulating osteoclastogenesis in vitro.16-18
Receptors for these cytokines are known to be expressed on the
osteoblast cell surface, where they can initiate signal transduction
via the recruitment and subsequent homodimerization or
heterodimerization of membrane-associated glycoprotein (gp)
130.19 This results in the subsequent activation of the
Janus family of tyrosine kinases (Jak1, Jak2, and Tyk2), which,
once activated, phosphorylate specific tyrosine residues within the
cytoplasmic domain of gp130.20 This allows members of the
STAT (signal transducer and activator of transcription) family
of transcription factors (STAT3 and STAT1) to bind gp130, where
they also undergo tyrosine phosphorylation by Jak. Once phosphorylated,
STATs form either homodimers or heterodimers and then translocate to
the nucleus, where they bind specific promoter elements within
their various response genes (reviewed by Heinrich et
al21).
Although the sequence of events occurring following STAT activation has
been well elucidated, factors modulating this activation are less
understood. Here we report that heparin acts synergistically with IL-11
to induce STAT3 activation by a mechanism that is independent of either
STAT3 tyrosine or serine phosphorylation. In addition, we report that
this results in enhanced osteoclast formation and activity, a finding
that may account for the increase in bone resorption that we have
observed in our animal models of heparin-induced osteoporosis.
Reagents
Calvaria and bone marrow cell isolation
Bone marrow cells were obtained from the femurs of 30-day-old
Swiss Webster mice.16 Briefly, to obtain bone marrow
cells, both ends of the disarticulated femoral bone were cut, and the marrow flushed out with phenol red-free In vitro TRAP assay Bone marrow cells (2 × 105/cm2) and murine calvaria cells (4 × 105/cm2) were cocultured in 24-well plates containing 13-mm Thermanox coverslips (NUNC, Naperville, IL) in the absence or presence of heparin (10 or 25 µg/mL), IL-11 (20 ng/mL), or a combination of the two. Every 3 days, fresh media and drug were added to existing media. Following a 9-day incubation, cells adherent to the 13 mm round Thermanox coverslips were fixed for 30 seconds with a citrate/acetone solution and then stained for tartrate-resistant acid phosphatase (TRAP) (procedure no. 386; Sigma Chemical, St Louis, MO) as described previously.16 The coverslips were then air dried, mounted onto slides, and the number of TRAP-positive (TRAP+) multinucleated cells (MNCs) determined microscopically at × 200 magnification.Osteoclastic pit formation assay Osteoclast activation was assessed by measuring the area of resorptive pits formed on the surface of smooth cortical bone slices. Briefly, cocultures of mouse calvaria and bone marrow cells were maintained on top of 1.0 cm2 cortical bone slices in the absence or presence of heparin (10 or 25 µg/mL), IL-11 (20 ng/mL), or a combination of the 2. Twenty-one days later, the cells were solubilized with 0.1% Triton X-100 (Bio-Rad, Hercules, CA) and the bone slices stained with 0.1% hematoxylin to allow for the visualization of resorption pits under light microscopy. Pit area was quantified using the computer imaging software system Northern Eclipse (Empix, Mississauga, ON, Canada).Cell lysis and nuclear extract preparation Calvaria cells were cultured to 70% to 80% confluency in -MEM containing 10% FCS and then stimulated for 20 minutes with either heparin (25 µg/mL), IL-11 (20 ng/mL), or a combination of the 2. The cells were then rinsed once with ice-cold
phosphate-buffered saline (PBS), isolated using a cell scraper,
pelleted by centrifugation, and then lysed with a hypotonic buffer (10 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid], pH
7.9; 1.5 mM MgCl2; 10 mM KCl; 0.5 mM dithiothreitol [DTT]; and 0.5 mM phenylmethylsulfonyl fluoride [PMSF]). The
nuclear pellet was then isolated by centrifugation and resuspended in 20 mM HEPES, pH 7.9, containing 420 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA (ethylenediaminetetraacetic acid), 0.5 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 25% glycerol. Protein concentrations of the nuclear extracts were measured using a Bio-Rad protein assay (Bio-Rad, Hercules, CA) prior to their use in the electrophoretic mobility shift assay (EMSA).
Electrophoretic mobility shift assays EMSAs were performed as described previously.22 Briefly, a double-strand synthetic consensus oligonucleotide based on the serum-inducible element of the c-fos promoter (SIE) (5'-GTG CAT TTC CCG TAA ATC TTG TCT ACA-3') was 5' end-labeled with [ -32P]adenosine triphosphate
([-32P]ATP) using polynucleotide T4
kinase (Boehringer Mannheim, Mannheim, Germany). Nuclear
extracts (5 µg) were then incubated with 3 µg of poly(dIdC)
(Pharmacia Biotech, Baie d'Urfe, QC, Canada) for 15 minutes
on ice before adding 100 000 cpm of the radiolabeled probe in 20 mM
HEPES, pH 7.9, containing 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM DTT, 0.5 mM PMSF, and 25% glycerol. For supershift assays, nuclear extracts were preincubated with anti-STAT3 antibody for
1 hour on ice. Competitions were performed with either the unlabeled
homologous probe or an oligonucleotide mutated in the DNA binding
region (5'-GTG CAT CCA CCG TAA ATC TTG TCT ACA-3'). After a 30-minute
incubation at room temperature, DNA-protein complexes were run on a 4%
native polyacrylamide gel, visualized by autoradiography, and
quantified using a PhosphoImager (Molecular Dynamics, Sunnyvale, CA).
Luciferase reporter gene assay The STAT3 reporter gene construct pTAL-LucSIE was constructed by inserting 3 copies of an annealed oligonucleotide corresponding to the SIE element from the human c-fos gene22 into the KpnI and XmaI sites upstream of the cytomegalovirus (CMV) minimal promoter of the luciferase reporter vector pTAL-Luc (Clontech, Palo Alto, CA). Calvaria cells were grown on 100-mm dishes and transfected with a mixture of plasmid containing the STAT3 reporter contructs (4 µg) and a Renilla luciferase expression plasmid (1 µg; Promega, Madison, WI) using lipofectin reagent as described by the manufacturer (Canadian Life Technologies, Burlington, ON, Canada). Transfected cells were then left untreated or were treated with heparin (25 µg/mL), IL-11 (20 ng/mL), or heparin plus IL-11 (25 µg/mL and 20 ng/mL, respectively) for 8 hours. The cells were then lysed and assayed for luciferase activities using the Dual Luciferase Reporter (DLR) Assay System according to the manufacturer's instructions (Promega). Luciferase activities were normalized to the internal control Renilla luciferase activity and assayed for luciferase activity as directed. Each sample was performed in triplicate in a single experiment and repeated in 4 separate experiments.Immunoprecipitation and immunoblotting Murine calvaria cells were grown to subconfluency in-MEM
containing 10% FCS. Cells were then treated with IL-11 (20 ng/mL), heparin (25 µg/mL), or heparin plus IL-11 (25 µg/mL and 20 ng/mL, respectively). After a 10-minute incubation at 37°C, the cells were
washed and then lysed with 1% deoxycholic acid and Triton X-100 in 50 mM Tris (tris(hydroxymethyl)aminomethane)-HCl (pH 7.2) containing
the protease and phosphatase inhibitors leupeptin (5 µg/mL),
aprotinin (5 µg/mL), pepstatin A (1 µg/mL), PMSF (1 mM), and EDTA
(0.25 mM). Supernatants of the cell extracts were then incubated
overnight at 4°C with 2 µg of either anti-gp130, anti-Jak-2, or
anti-STAT3 antibody and then incubated with protein A sepharose
(Pharmacia Biotech) for 1 hour to immunoprecipitate antigen/antibody
complexes. Immunoprecipitates were washed 3 to 5 times with lysis
buffer, boiled, and then subjected to 7.5% sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis before being
transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad).
Membranes were blocked with 5% casein for 1 hour at room temperature
and then incubated with anti-gp130, anti-Jak-2, or anti-STAT3 antibody
for 2 hours. The blots were then incubated with horseradish peroxidase
(HRP)-conjugated secondary antibodies (Abs) and protein visualized
using an enhanced chemiluminescent system. Identical samples
were run on a second gel, transferred to PVDF membranes, and anti-pTyr
or anti-pSer727 antibodies were used to probe for phosphorylation.
[32P]orthophosphate labeling Calvaria cells were starved for 2 hours in phosphate-free media-MEM (Sigma) containing 10% fetal calf serum that
had been dialyzed against a HEPES buffer (1.8 mM CaCl2, 5mM
KCl, 0.8 mM MgSO4, 110 mM NaCl, 44 mM NaHCO3,
and 25 mM HEPES [pH 7.3]). [32P]orthophosphate was then
added to the medium to a final concentration of 0.1 mCi/mL (3.7 MBq;
5 mL labeling medium was used per 100-mm diameter dish).
Following a 2.5-hour incubation, cell lysates from heparin, IL-11, and
IL-11 plus heparin-treated calvaria cells were prepared and
immunoprecipitated with anti-STAT3 antibody as described above.
Following immunoblotting, membranes were washed overnight in
Tris-buffered saline with 0.05% Tween-20 (TBST) at 4°C
prior to autoradiography.
RNA extraction and Northern blot analysis Calvaria cells were plated at 5 × 105/10-cm dish and cultured for 2 days in-MEM containing 10% FCS and 100 U/mL
penicillin/100 µg/mL streptomycin. The cells were then treated with
heparin (25 µg/mL), IL-11 (20 ng/mL), or IL-11 (20 ng/mL) plus
heparin (25 µg/mL) for 6 days to examine RANKL
expression23 or for 24 hours to examine the expression of
gp130. Total RNA was isolated using the RNeasy mini kit from Qiagen
(Mississauga, ON, Canada). PolyA+ RNA was isolated from
total RNA using the Oligotex procedure (Qiagen).
PolyA+ RNA (2.0 µg) was fractionated on a 1%
agarose/formaldehyde gel and transferred onto a nitrocellulose
membrane. The RNA was cross-linked to the membrane using a UV
cross-linker (Statalinker 2400; Stratagene Cloning Systems, La
Jolla, CA) prior to hybridization. -deoxycytidine triphosphate
(-dCTP) 32P-labeled cDNA probes were generated
by random priming (Roche Molecular Biochemicals, Laval, QC,
Canada); 717- and 734-base pair polymerase chain reaction
products corresponding to the partial coding region of RANKL and gp130,
respectively, were used as probes. Membranes were exposed to Kodak
X-Omat AP film (Rochester, NY) at  70°C for 1 to 3 days and
analyzed using a PhosphoImager (Molecular Dynamics). Blots were
stripped by boiling for 2 × 20 minutes in 0.1 × SSC/0.5%SDS and
rehybridized with additional probes. A partial cDNA fragment for GAPDH
was used as loading control.
Statistical analysis Analysis of variance was used to compare the results in the experimental groups with those in the controls. The significance of differences was determined using an unpaired Student t test with a Bonferroni correction for multiple comparisons. All data are expressed as a mean ± SEM.
The effect of heparin on IL-11-induced in vitro osteoclast formation IL-11's ability to induce osteoclast formation was assessed by examining its ability to stimulate TRAP+ MNC formation in cocultures of murine bone marrow and calvaria cells. As shown in Figure 1, IL-11 stimulated TRAP+ MNC formation in a dose-dependent manner from concentrations as low as 6.3 ng/mL to concentrations as high as 50.0 ng/mL. In contrast, heparin alone had no effect on the formation of TRAP+ MNCs (Figure 2A). However, when cocultures were treated with both heparin and IL-11, IL-11's ability to stimulate TRAP+ MNC formation was enhanced more than 6-fold (Figure 2A).
To establish that the TRAP+ MNCs formed were indeed osteoclasts and thus capable of resorbing bone, cocultures of murine calvaria and bone marrow cells were grown over smooth cortical bone slices. Following a 21-day incubation, the cells were lysed and the cortical bone slices stained with hematoxylin to quantify the area of bone resorbed using light microscopy. Figure 2B demonstrates that the TRAP+ MNCs formed in the presence of IL-11 were able to resorb bone and that this activity was increased 2-fold in the presence of heparin. Taken together, these results suggest that heparin acts synergistically with IL-11 to increase not only the formation of osteoclasts but also their activity. The effects of heparin on IL-11-induced DNA binding and transactivation of STAT3 To determine the mechanism by which heparin enhanced IL-11-induced TRAP+ MNC formation, we treated calvaria cells with IL-11 in the presence or absence of heparin and then quantified STAT-DNA complex formation by EMSA using radiolabeled SIE oligonucleotides. The SIE element is a well-established target of activated STATs, forming STAT-DNA complexes upon incubation in vitro.9 As shown in Figure 3, nuclear extracts isolated from IL-11-stimulated cells were able to form protein-DNA complexes containing STAT3 homodimers and, to a lesser extent, STAT1/STAT3 heterodimers. No protein-DNA complexes were detected in the presence of excess cold SIE or in the presence of a DNA probe that differed from native SIE by 3 nucleotides (mSIE). Nuclear extracts isolated from cells treated with heparin alone did not form protein-DNA complexes with radiolabeled SIE, suggesting that heparin alone was unable to induce STAT activation. However, increased protein-DNA complex formation was detected when the nuclear extracts isolated from cells stimulated with IL-11 and heparin were compared with those stimulated with IL-11 alone. When quantified using phosphoimaging analysis, heparin was found to increase IL-11-induced STAT binding to SIE by 2-fold. These results demonstrate that heparin synergizes with IL-11, increasing the amount of activated STAT homodimer and heterodimer binding to DNA.
To determine if the increase in STAT3-DNA complex formation resulted in
increased transcriptional activation of STAT3-responsive genes, murine
calvaria cells were transfected with a luciferase reporter plasmid that
contained an SIE element upstream of a CMV promotor. The cells were
then treated with IL-11 in the presence or absence of heparin for 24 hours. As shown in Figure 4, luciferase activity was significantly increased over control values when transfected cells were treated with IL-11. In contrast, luciferase activity was not significantly increased when transfected cells were
treated with heparin alone. However, when transfected cells were
treated with both heparin and IL-11, heparin was found to enhance
IL-11's ability to induce luciferase activity by more than 2-fold.
The effect of heparin on IL-11-induced tyrosine phosphorylation of gp130, Jaks, and STATs in murine calvaria cells To elucidate the mechanism by which heparin stimulated IL-11-induced STAT activation, proteins involved in the IL-11 signaling pathway were examined for increased tyrosine phosphorylation following their immunoprecipitation from murine calvaria cell lysates. Because tyrosine phosphorylation of the Jak/STAT family proteins has been shown to be essential for gp130-mediated signal transduction,20-22,24,25 we performed immunoprecipitation on whole cell lysates isolated from cells treated with heparin, IL-11, or a combination of the 2 for 10 minutes. The tyrosine phosphorylation status of gp130, Jak1, Jak2, Tyk2, STAT1, and STAT3 was then determined by immunoblotting. Figure 5A demonstrates that IL-11, but not heparin, induced tyrosine phosphorylation of gp130 and that tyrosine phosphorylation of gp 130 by IL-11 was not increased further in the presence of heparin (Figure 5A). IL-11 also induced tyrosine phosphorylation of Jak2 (Figure 5B). However, as shown in Figure 5, tyrosine phosphorylation of Jak 2 by IL-11 was not further amplified in the presence of heparin; nor did it occur in the presence of heparin alone. Neither Jak1 nor Tyk2 tyrosine phosphorylation could be detected in calvaria cells treated with the above conditions (data not shown). STAT3 (Figure 5C) and, to a lesser extent, STAT1 (data not shown) were also found to be tyrosine phosphorylated in response to IL-11 treatment. However, similar to gp130 and Jak2, heparin alone had no effect on the tyrosine phosphorylation status of either STAT3 or STAT1, and no further tyrosine phosphorylation was observed when the cells were treated with IL-11 and heparin. Collectively, these results demonstrate that heparin does not alter the tyrosine phosphorylation status of either gp130, JAK2, or STAT3, suggesting that alternative mechanisms of heparin-induced synergy with IL-11 must be involved.
The effect of heparin on IL-11-induced STAT-3 serine phosphorylation Phosphorylation of Ser727 has previously been shown to increase STAT3 activation.26,27 To investigate whether serine phosphorylation of STAT3 was important in the synergy between heparin and IL-11, we labeled calvaria cells with [32P]orthophosphate for 2.5 hours and then treated the cells with heparin, IL-11, or IL-11 and heparin for 10 minutes. STAT3 immunoprecipitates were then analyzed by both immunoblotting for Ser727 phosphorylation and by autoradiography (Figure 6). Figure 6B demonstrates that incubation of murine calvaria cells with IL-11 resulted in increased Ser727 phosphorylation. In contrast, heparin alone had no effect on Ser727 phosphorylation, nor was it found to enhance IL-11-induced phosphorylation of Ser727. These results demonstrate that heparin's ability to enhance IL-11-induced STAT3 activation is independent of STAT3 Ser727 phosphorylation.
Because STAT3 is known to contain phosphoserine residues other than Ser727,28-30 we also explored the possibility that heparin may be increasing serine phosphorylation of STAT3 at these sites. As shown in Figure 6C, basal phosphorylation of STAT3 was not altered in the presence of heparin. Although stimulation with IL-11 did result in enhanced STAT3 phosphorylation, the simultaneous addition of heparin did not further increase total phosphorylation. Because total phosphorylation of STAT3 was not affected by heparin either alone or in the presence of IL-11, these results strongly suggest that heparin is not inducing serine phosphorylation of STAT3 at sites other than Ser727. Effect of heparin on IL-11-induced gp130 and RANKL expression Because heparin enhances IL-11-induced STAT3 transactivation, we next examined its ability to enhance the transcription of genes that contain STAT3 binding elements within their promoters. Of those that are capable of modulating osteoclast formation, gp130 and RANKL have recently been demonstrated to play a role in STAT3-mediated osteoclast formation.31-33 We therefore performed Northern blot analysis to examine the expression of both RANKL and gp130 in calvaria cells treated with heparin, IL-11, or a combination of the 2. Figure 7A demonstrates that RANKL expression was induced by IL-11, whereas heparin alone had no effect. However, when heparin was combined with IL-11, the expression of RANKL was increased 3.8-fold over that seen with IL-11 alone. Similar results were observed when the expression of gp130 was examined (Figure 7B). When taken together, these results provide a mechanism by which heparin, by increasing IL-11-induced STAT3-DNA binding, can enhance IL-11-induced osteoclast formation.
We previously developed an animal model of heparin-induced osteoporosis in an attempt to examine heparin's effects on bone. Using this model, we showed that heparin induces both a time- and dose-dependent decrease in cancellous bone volume and that this, in part, results from an increase in osteoclast number and activity.13,14 In the current study, we demonstrate that heparin acts synergistically with IL-11 to induce both STAT3 activation and in vitro osteoclast formation. Furthermore, we demonstrate that the effect of heparin on IL-11-induced STAT3 activation is independent of either STAT3 tyrosine or serine phosphorylation but leads to increased expression of both gp130 and RANKL. To our knowledge, this is the first study demonstrating a synergistic effect between a glycosaminoglycan and a cytokine signaling cascade and suggests a possible mechanism by which heparin may mediate bone loss when given long-term. Our results are novel in that they clearly demonstrate heparin's ability to synergistically enhance IL-11-induced osteoclast formation and activity in vitro. IL-11 has been shown to act synergistically with other cytokines such as IL-3, stem cell factor, macrophage colony-stimulating factor (M-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF) to stimulate megakaryocytopoiesis 34-36 and erythropoiesis 37-39 in vivo as well as to enhance both platelet and neutrophil recovery following sublethal irradiation.40 However, to date no other factors have been shown to enhance IL-11's ability to induce osteoclast formation. Here we report that heparin enhances the formation of osteoclasts by synergizing with IL-11 to induce RANKL expression (Figure 7A). Osteoblast expression of RANKL, in the presence of M-CSF, is known to be required for the formation of mature osteoclasts.41-45 In addition, IL-11 as well as other gp130 cytokines are known to induce RANKL in a STAT3-dependent manner.23,31 In the current study, we confirm IL-11s' ability to induce RANKL and demonstrate that heparin has the ability to enhance RANKL expression in the presence of IL-11. Although it is possible that heparin in combination with IL-11 may have concurrent effects on osteoclast precursors, the effects of heparin on IL-11-induced RANKL expression suggest a likely mechanism by which heparin enhances osteoclast formation both in vitro and in vivo. IL-11-type cytokines such as IL-6 have also been shown to up-regulate the expression of gp130 on the surface of both human vascular smooth muscle and HepG2 cells.46,47 Because gp130, like RANKL, contains a STAT3 binding element within its promoter,32 we also examined the ability of heparin to enhance IL-11-induced gp130 expression. We found that, similar to its effect on RANKL, heparin was able to increase gp130 expression in the presence of IL-11. Previous studies have shown that increased gp130 expression can result in increased osteoclast formation in vitro.33 This suggests that up-regulation of gp130 may amplify osteoclast formation by further enhancing RANKL expression and would explain why, in the current study, heparin was able to enhance IL-11-induced osteoclast formation 6-fold even though IL-11-induced STAT3 activation was enhanced only 2-fold. Heparin is known to bind a number of cytokines and/or growth factors and to thus alter the ability of such factors to bind to their respective receptors. For example, heparin has been shown to bind basic fibroblast growth factor (bFGF), suppressing in vitro collagen synthesis by 21-day-old fetal rat calvariae to a much greater extent than either heparin or bFGF alone.48 In the current study, we show that both IL-11-induced STAT3-DNA complex formation and transactivation are enhanced by heparin (Figures 3 and 4). To explain these findings, we initially hypothesized that heparin might be enhancing IL-11-induced STAT3 activation by binding IL-11 and thereby increasing IL-11-IL-11 receptor (IL-11R) interactions. However, binding studies with radiolabeled IL-11 failed to show increased binding of IL-11 on the calvaria cell surface in the presence of heparin (data not shown). In addition, neither gp130, JAK2, nor STAT3 tyrosine phosphorylation was altered when heparin was added in the presence of IL-11. When taken together, these results suggest that the mechanism by which heparin increases STAT3 activation is independent of IL-11-IL-11R interactions. Although tyrosine phosphorylation is the primary regulator of STAT
activity, maximal activation of STAT requires both serine and tyrosine
phosphorylation. For example, STAT3 has been shown to be phosphorylated
not only on Tyr705 but also on Ser727, which is located within the
putative mitogen-activated protein (MAP) kinase recognition
sequence PMSP at the -COOH terminus. Although phosphorylation of Tyr705
is a prerequisite of STAT3 dimerization and DNA binding,
phosphorylation of Ser727 has been demonstrated to be required for
maximal STAT3 transactivation. In addition, there is evidence to
suggest that STAT3 may be phosphorylated on serine residues other than
Ser727 and that these may also enhance not only STAT3 transactivation
but also STAT3-DNA binding.29,30 In this study, Ser727 was
not phosphorylated by heparin alone; nor did heparin alter the
phosphorylation status of Ser727 in the presence of IL-11. The lack of
involvement of Ser727 in heparin's ability to enhance IL-11-induced
STAT3-DNA binding agrees with previous studies that have shown that
complex formation is unaffected by a STAT3 Ser727 In summary, we have demonstrated that heparin enhances IL-11-induced STAT3 activation by a mechanism that does not involve either tyrosine or serine phosphorylation of STAT3 but which leads to the increased expression of both gp130 and RANKL. This provides a plausible mechanism by which heparin may synergize with IL-11 in the formation of osteoclasts and helps to explain why patients treated with long-term heparin have measurable decreases in bone density that can translate to symptomatic fractures.
Submitted August 21, 2001; accepted May 22, 2002.
Supported by a "Premier's Research Excellence Award" to S.G.S. Also supported by the Heart and Stroke Foundation of Ontario (grant no. T 4153) and the Canadian Institutes of Health Research (grant no. MOP-53333). S.G.S. is a Research Scholar of the Heart and Stroke Foundation of Canada.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Stephen G. Shaughnessy, Hamilton Civic Hospitals Research Center, 711 Concession St, Hamilton, ON, Canada, L8V 1C3; e-mail: sshaughnessy{at}thrombosis.hhscr.org.
1. Avioli LV. Heparin-induced osteopenia: an appraisal. Adv Exp Med Biol. 1975;52:375-387[Medline] [Order article via Infotrieve]. 2. Griffith CC, Nichols G, Asher JD, Flanagan B. Heparin osteoporosis. JAMA. 1965;193:85-88. 3. Jaffe MD, Willis PW. Multiple fractures associated with long term sodium heparin therapy. JAMA. 1965;193:152-154[CrossRef][Medline] [Order article via Infotrieve]. 4. Miller WE, DeWolfe VG. Osteoporosis resulting from heparin therapy. Cleveland Clin Q. 1966;33:31-34[Medline] [Order article via Infotrieve]. 5. Dahlman TC, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol. 1994;170:1315-1320[Medline] [Order article via Infotrieve].
6.
Squires JW, Pinch LWC.
Heparin-induced spinal fractures.
JAMA.
1979;241:2417-2418 7. Murphy MS, John PR, Mayer AD, Buckels JAC, Kelly DA. Heparin therapy and bone fractures. Lancet. 1992;340:1098[Medline] [Order article via Infotrieve]. 8. Monreal M, Olive A, Lafoz E, Del Rio L. Heparins, coumarin, and bone density. Lancet. 1991;338:706[Medline] [Order article via Infotrieve]. 9. Rupp WM, McCarthy HB, Rohde TD, et al. Risk of osteoporosis in patients treated with long-term intravenous heparin therapy. Curr Surg. 1982;39:419-422[Medline] [Order article via Infotrieve]. 10. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol. 1994;170:862-869[Medline] [Order article via Infotrieve]. 11. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994;71:7-11[Medline] [Order article via Infotrieve]. 12. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993;168:1265-1270[Medline] [Order article via Infotrieve].
13.
Muir JM, Andrew M, Hirsh J, et al.
Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo.
Blood.
1996;88:1314-1320
14.
Muir JM, Hirsh J, Weitz JI, et al.
A histomorphometric comparison of the effects of heparin and low molecular weight heparin on cancellous bone in rats.
Blood.
1997;89:3236-3242 15. Elias JA, Tang W, Horowitz MC. Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production. Endocrinology. 1995;136:489-498[Abstract]. 16. Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine. 2000;12:613-621[CrossRef][Medline] [Order article via Infotrieve].
17.
Romas E, Udagawa N, Zhou H, et al.
The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures.
J Exp Med.
1996;183:2581-2591 18. Girasole G, Passeri G, Jilka RL, Manolagas SC. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 1994;93:1516-1524[Medline] [Order article via Infotrieve]. 19. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell. 1994;76:253-262[CrossRef][Medline] [Order article via Infotrieve].
20.
Stahl N, Boulton TG, Farruggella T, et al.
Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 21. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Interleukin-6 type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334:297-314[Medline] [Order article via Infotrieve].
22.
Zhong Z, Wen Z, Darnell J Jr.
Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6.
Science.
1994;264:95-98
23.
Yasuda H, Shima N, Nakagawa N, et al.
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.
Proc Natl Acad Sci U S A.
1998;95:3597-3602
24.
Lütticken C, Wegenka UM, Yuan J, et al.
Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130.
Science.
1994;263:89-92
25.
Narazaki M, Witthuhn BA, Yoshida K, et al.
Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130.
Proc Natl Acad Sci U S A.
1994;91:2285-2289 26. Wen Z, Zhong Z. Darnell JE Jr. Maximal activation of transcription by STAT1 and STAT3 requires both tyrosine and serine phosphorylation. Cell. 1995;82:241-250[CrossRef][Medline] [Order article via Infotrieve]. 27. Schuringa J, Jonk LJC, Dokter WHA, Vellenga E, Kruijer W. Interleukin-6-induced STAT3 transactivation and Ser 727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. Biochem J. 2000;347:89-96[CrossRef][Medline] [Order article via Infotrieve].
28.
Zhang X, Blenis J, Li H, Schindler C, Chen-Kiang S.
Requirement of serine phosphorylation for formation of STAT-promoter complexes.
Science.
1995;267:1990-1994
29.
Ng J, Cantrell D.
STAT3 is a serine kinase target in T Lymphocytes: interleukin 2 and T cell antigen receptor signals converge upon serine 727.
J Biol Chem.
1997;272:24542-24549 30. Chung J, Uchida E, Grammar TC, Blenis J. STAT3 serine phosphorylation by ERK-dependent and independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol. 1997;17:6508-6516[Abstract].
31.
O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC.
STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-
32.
O'Brien CA, Manolagas SC.
Isolation and characterization of the human gp130 promoter: regulation by STATS.
J Biol Chem.
1997;272:15003-15010 33. O'Brien CA, Lin SC, Bellido T, Manolagas SC. Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6 type cytokines. J Cell Biochem. 2000;79:532-541[CrossRef][Medline] [Order article via Infotrieve]. 34. Bruno E, Briddell RA, Cooper RJ, Hoffman R. Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells. Exp Hematol. 1991;19:378-381[Medline] [Order article via Infotrieve].
35.
Neben TY, Loebelenz J, Hayes L, et al.
Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice.
Blood.
1993;81:901-908
36.
Weich NS, Wang A, Fitzgerald M, et al.
Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro.
Blood.
1997;90:3893-3902
37.
Quesniaux VF, Clark SC, Turner K, Fagg B.
Interleukin-11 stimulates multiple phases of erythropoiesis in vitro.
Blood.
1992;80:1218-1223 38. Rodriguez MH, Arnaud S, Blanchet JP. IL-11 directly stimulates murine and human erythroid burst formation in semisolid cultures. Exp Hematol. 1995;23:545-550[Medline] [Order article via Infotrieve]. 39. de Haan G, Dontje B, Engel C, Loeffler M, Nijhof W. In vivo effects of interleukin-11 and stem cell factor in combination with erythropoietin in the regulation of erythropoiesis. Br J Haematol. 1995;90:783-790[Medline] [Order article via Infotrieve]. 40. Galmiche MC, Vogel CA, Delaloye AB, et al. Combined effects of interleukin-3 and interleukin-11 on hematopoiesis in irradiated mice. Exp Hematol. 1996;24:1298-1306[Medline] [Order article via Infotrieve]. 41. Wong BR, Josien R, Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol. 1999;65:715-724[Abstract]. 42. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319[CrossRef][Medline] [Order article via Infotrieve]. 43. Lacey D, Timms E, Tan H, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176[CrossRef][Medline] [Order article via Infotrieve].
44.
Fuller K, Wong B, Fox S, Choi Y, Chambers T.
TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.
J Exp Med.
1998;188:997-1001 45. Kong Y, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323[CrossRef][Medline] [Order article via Infotrieve].
46.
Klouche M, Bhakdi S, Hemmes M, Rose-John S.
Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor.
J Immunol.
1999;163:4583-4589 47. Schooltink H, Schmitz-Van de Leur H, Heinrich PC, Rose-John S. Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells. FEBS Lett. 1992;297:263-265[CrossRef][Medline] [Order article via Infotrieve].
48.
Hurley MM, Kessler M, Gronowicz G, Raisz LG.
The interaction of heparin and basic fibroblast growth factor on collagen synthesis in 21-day fetal rat calvariae.
Endocrinology.
1992;130:2675-2682
49.
Chung CD, Liao J, Liu B, et al.
Specific inhibition of Stat3 signal transduction by PIAS3.
Science.
1997;278:1803-1805 50. Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene. 2000;19:2638-2644[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. M. Nelson and I. A. Greer The potential role of heparin in assisted conception Hum. Reprod. Update, November 1, 2008; 14(6): 623 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Handschin, M. Egermann, O. Trentz, G. A. Wanner, H.-J. Kock, G. Zund, and O. A. Trentz Cbfa-1 (Runx-2) and Osteocalcin Expression by Human Osteoblasts in Heparin Osteoporosis in Vitro Clinical and Applied Thrombosis/Hemostasis, October 1, 2006; 12(4): 465 - 472. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Rajgopal, M. Butcher, J. I. Weitz, and S. G. Shaughnessy Heparin Synergistically Enhances Interleukin-11 Signaling through Up-regulation of the MAPK Pathway J. Biol. Chem., July 28, 2006; 281(30): 20780 - 20787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kelly, L. J. Suva, Y. Huang, V. MacLeod, H.-Q. Miao, R. C. Walker, and R. D. Sanderson Expression of Heparanase by Primary Breast Tumors Promotes Bone Resorption in the Absence of Detectable Bone Metastases Cancer Res., July 1, 2005; 65(13): 5778 - 5784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. H. Lerner NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION Critical Reviews in Oral Biology & Medicine, March 1, 2004; 15(2): 64 - 81. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
B ligand (RANKL) and glycoprotein (gp) 130. When taken
together, these findings suggest a plausible mechanism by which heparin
may cause increased osteoclastogenesis and therefore bone loss when
administered long-term.
(Blood. 2002;100:2530-2536)
Ala
mutation.
receptor components.
Science.
1994;263:92-95